Mixed Short Interest in Drug & Medical Stocks (June 2007)

Health and Healthcare

Published: June 24, 2007 12:16 pm

As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but its short interest is not representative of its real size or activity because it is an ADR and less active here compared to U.K. trade volume. We ranked hese in terms of percentages with the largest increase in short interest first.

STOCK (Ticker)             JUNE07    MAY07    Change
GlaxoSmithkline (GSK)    7.74M       4.15M    +86%
Boston Scientific (BSX) 32.07M    24.06M    +33.3%
Wyeth (WYE)                         3.3M    10.37M    +28.3%
Labcorp (LH)                      4.11M       3.21M    +28%
Bristol-Myers (BMY)       26.95M    23.85M    +13%
Schering-Plough (SGP) 16.79M    15.27M    +9.9%
Medtronic (MDT)             16.11M    15.19M       +6%
Pfizer (PFE)                      54.48M    52.12M    +4.5%
Quest Diagnost. (DGX) 18.00M    17.54M    +2.6%
Merck (MRK)                      22.82M    22.55M    +1.2%
Eli Lilly (LLY)                      13.77M    14.07M       -2.1%
J&J (JNJ)                            15.37M    16.16M       -4.9%
Zimmer Holdings (ZMH)    3.89M       4.13M       -5.8%
St. Jude MEdical (STJ)       6.53M       7.13M       -8.4%
Genentech (DNA)                6.87M       8.16M       -15.9%
Abbott Labs (ABT)             11.74M    16.39M       -28.3%

Jon C. Ogg
June 24, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Get Ready To Retire ^(Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future